Novo Nordisk Hopes Victoza's EU Clearance Bodes Well For U.S.
GLP-1 inhibitor approved in Europe without restrictions on use, but Novo Nordisk will conduct a five-year cardiovascular outcomes trial.
GLP-1 inhibitor approved in Europe without restrictions on use, but Novo Nordisk will conduct a five-year cardiovascular outcomes trial.